Following a recent slew of regulations, pharma companies are increasingly struggling to roll out their products, falling at the commercialisation hurdle. US and EU policies have created a perfect storm for the industry, raising costs and reducing successful launches of new drugs. While many firms are turning to AI for research support, I predict that the technology’s greatest value will lie in this area, and in fixing this challenge. By identifying the patient subgroups who would benefit the…